All In MedTech

FDA Clearance Tracker · P990027-S011

BAUSCH & LOMB TECHNOLAS 217Z ZYOPTIX LASER SYSTEM

A PMA supplement is a change to a device that already has premarket approval, such as a new indication, a design change or a manufacturing change.

Last checked: Nov 20, 2026Latest source record: May 1, 2009 (this decision)Source: openFDAMethods & limitations

PMA supplement

Decided

May 1, 2009

Approved

Time to decision

240 days

Received Sep 3, 2008. Calendar days, including time FDA spent waiting on the applicant.

Pathway

PMA supplement

Normal 180 Day Track

Device class

Class III

The decision

FDA number
P990027-S011
Device name
BAUSCH & LOMB TECHNOLAS 217Z ZYOPTIX LASER SYSTEM
Applicant location
MüNchen
Received
Sep 3, 2008
Decided
May 1, 2009
Decision
Approved
Supplement type
Normal 180 Day Track
Reason for supplement
Change Design/Components/Specifications/Material
Original approval
P990027

Device type

Device class
Class III
Specialty
Ophthalmology

Every decision under product code LZS

FDA's approval statement

As written in FDA's record.

APPROVAL FOR THE DYNAMIC ROTATIONAL EYE TRACKER WITH IRIS RECOGNITION FOR USE WITH THE BAUSCH & LOMB TECHNOLAS 217Z ZYOPTIX LASER SYSTEM FOR PERSONALIZED VISIONCORRECTION. THE DEVICE, AS MODIFIED, WILL BE MARKETED UNDER THE TRADE NAME TECHNOLAS 217Z ZYOPTIX LASER SYSTEM FOR PERSONALIZED VISION CORRECTION AND IS INDICATED FOR:1) WAVEFRONT-GUIDED LASER ASSISTED IN-SITU KERATOMILEUSIS (LASIK) TREATMENTS FOR THE REDUCTION ORELIMINATION OF MYOPIA WITH SPHERE UP TO -7.00 D AND CYLINDER UP TO -3.00 D AND MRSE < = 7.50 D ATTHE SPECTACLE PLANE:REDUCTION OR ELIMINATION OF MYOPIA (NEARSIGHTEDNESS) FROM -1.00 D TO -7.00 D WITH LESS THAN -3.00 D ASTIGMATISM;2) REDUCTION OR ELIMINATION OF MYOPIC ASTIGMATISM UP TO -12.00 D MRSE, WITH SPHERE BETWEEN > -7.00 D TO -10.99 D AND CYLINDER BETWEEN 0.00 AND < -3.00 D; AND 4) REDUCTION OR ELIMINATION OF LOW-TO-MODERATE NATURALLY OCCURRING HYPEROPIA UP TO +4.00 D MRSE, WITH SPHERE BETWEEN +1.00 D TO +4.00 D WITH OR WITHOUT REFRACTIVE ASTIGMATISM UP TO+2.00 D AT THE SPECTACLE PLANE.

Source documents

Other decisions for Technolas Perfect Vision GmbH

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

4 more FDA decisions with a free account

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.